US deal helps Dechra

ANIMAL pharmaceuticals firm Dechra has seen first quarter revenues jump by 6%.

The firm, which operates the Dales Pharmaceuticals business in Skipton, has benefited from a US acquisition and said the performance was set against a “soft
comparator” period when the business was adversely affected by the timing of export orders and supply issues in the US.

Most of the growth came from the US where sales leapt by 51%, largely down to the Phycox business it acquired in May for £6m.

The company said: “Group trading in the first quarter has been in line with management expectations and was consistent with the positive momentum experienced in the second half of our prior financial year.”

In the year to June the company reported underlying profit before tax of £39.9m (2013: £33.5m) on sales of of £193.6m, up from £189.2m in 2013.

Close